These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38776275)

  • 21. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.
    Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE
    F1000Res; 2021; 10():614. PubMed ID: 35106137
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy.
    Spaull R; Soo AK; Batzios S; Footitt E; Whiteley R; Mink JW; Carr L; Gissen P; Kurian MA
    Neurology; 2024 Aug; 103(3):e209615. PubMed ID: 38976822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A survival analysis of ventricular access devices for delivery of cerliponase alfa.
    Craven CL; Gissen P; Bower R; Lee L; Aquilina K; Thompson DNP
    J Neurosurg Pediatr; 2022 Jan; 29(1):115-121. PubMed ID: 34624852
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
    Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A
    J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neurofilament light is a treatment-responsive biomarker in CLN2 disease.
    Ru Y; Corado C; Soon RK; Melton AC; Harris A; Yu GK; Pryer N; Sinclair JR; Katz ML; Ajayi T; Jacoby D; Russell CB; Chandriani S
    Ann Clin Transl Neurol; 2019 Dec; 6(12):2437-2447. PubMed ID: 31814335
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy.
    Huang WC; Ohnsman CM; Atiskova Y; Falabella P; Spitzer MS; Schulz A; Dulz S
    Invest Ophthalmol Vis Sci; 2024 Jul; 65(8):45. PubMed ID: 39078732
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies.
    Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S
    Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical protocol. Administration of a replication-deficient adeno-associated virus gene transfer vector expressing the human CLN2 cDNA to the brain of children with late infantile neuronal ceroid lipofuscinosis.
    Crystal RG; Sondhi D; Hackett NR; Kaminsky SM; Worgall S; Stieg P; Souweidane M; Hosain S; Heier L; Ballon D; Dinner M; Wisniewski K; Kaplitt M; Greenwald BM; Howell JD; Strybing K; Dyke J; Voss H
    Hum Gene Ther; 2004 Nov; 15(11):1131-54. PubMed ID: 15610613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Language Delay in Patients with CLN2 Disease: Could It Support Earlier Diagnosis?
    Nickel M; Gissen P; Greenaway R; Cappelletti S; Hamborg C; Ragni B; Ribitzki T; Schulz A; Tondo I; Specchio N
    Neuropediatrics; 2023 Dec; 54(6):402-406. PubMed ID: 37329878
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).
    Katz ML; Coates JR; Sibigtroth CM; Taylor JD; Carpentier M; Young WM; Wininger FA; Kennedy D; Vuillemenot BR; O'Neill CA
    J Neurosci Res; 2014 Nov; 92(11):1591-8. PubMed ID: 24938720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy.
    Specchio N; Pietrafusa N; Trivisano M
    Ther Clin Risk Manag; 2020; 16():213-222. PubMed ID: 32280231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Visual perception and macular integrity in non-classical CLN2 disease.
    Atiskova Y; Wildner J; Wibbeler E; Nickel M; Spitzer MS; Schwering C; Schulz A; Dulz S
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3693-3700. PubMed ID: 35652945
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Classic and Atypical Late Infantile Neuronal Ceroid Lipofuscinosis in Latin America: Clinical and Genetic Aspects, and Treatment Outcome with Cerliponase Alfa.
    Guelbert N; Espitia Segura OM; Amoretti C; Arteaga Arteaga A; Atanacio NG; Bazan Natacha S; Carvalho EDF; Carvalho de Andrade MDF; Denzler IM; Durand C; Ribeiro E; Giugni JC; González G; González Moron D; Guelbert G; Hernández Rodriguez ZJ; Embiruçu Emilia K; Kauffman MA; Mancilla NI; Marcon L; Marques Pereira A; Fischinger Moura de Souza C; Muñoz VA; Naranjo Flórez RA; Pessoa AL; Ruiz MV; Solano Villareal ML; Spécola N; Tavera LM; Tello J; Troncoso Schifferli M; Ugrina S; Vaccarezza MM; Vergara D; Villanueva MM
    Mol Genet Metab Rep; 2024 Mar; 38():101060. PubMed ID: 38469103
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease).
    Sindelar M; Dyke JP; Deeb RS; Sondhi D; Kaminsky SM; Kosofsky BE; Ballon DJ; Crystal RG; Gross SS
    Sci Rep; 2018 Oct; 8(1):15229. PubMed ID: 30323181
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravitreal enzyme replacement inhibits progression of retinal degeneration in canine CLN2 neuronal ceroid lipofuscinosis.
    Whiting REH; Robinson Kick G; Ota-Kuroki J; Lim S; Castaner LJ; Jensen CA; Kowal J; Nguyen A; Corado C; O'Neill CA; Katz ML
    Exp Eye Res; 2020 Sep; 198():108135. PubMed ID: 32634395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease.
    Lourenço CM; Sallum JMF; Pereira AM; Girotto PN; Kok F; Vilela DRF; Barron E; Pessoa A; Oliveira BM
    Arq Neuropsiquiatr; 2024 May; 82(5):1-8. PubMed ID: 38763144
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing
    Sondhi D; Kaminsky SM; Hackett NR; Pagovich OE; Rosenberg JB; De BP; Chen A; Van de Graaf B; Mezey JG; Mammen GW; Mancenido D; Xu F; Kosofsky B; Yohay K; Worgall S; Kaner RJ; Souwedaine M; Greenwald BM; Kaplitt M; Dyke JP; Ballon DJ; Heier LA; Kiss S; Crystal RG
    Sci Transl Med; 2020 Dec; 12(572):. PubMed ID: 33268510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First in man study of intravitreal tripeptidyl peptidase 1 for CLN2 retinopathy.
    Wawrzynski J; Martinez AR; Thompson DA; Ram D; Bowman R; Whiteley R; Gan C; Harding L; Mortensen A; Mills P; Gissen P; Henderson RH
    Eye (Lond); 2024 Apr; 38(6):1176-1182. PubMed ID: 38049626
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease.
    Kovacs KD; Patel S; Orlin A; Kim K; Van Everen S; Conner T; Sondhi D; Kaminsky SM; D'Amico DJ; Crystal RG; Kiss S
    Ophthalmol Retina; 2020 Jul; 4(7):728-736. PubMed ID: 32146219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.